| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.0098 | 0.7 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.049 | 0.8 |